What Is Letrozole? Dosage, Half-Life & How to Track It

What letrozole is and how it works

Letrozole shares its basic mechanism with anastrozole — a non-steroidal, reversible, competitive inhibitor of the aromatase enzyme — but binds with higher affinity, producing more complete suppression of estrogen synthesis at comparable doses. It’s considered the benchmark aromatase inhibitor in oncology for exactly that reason.

FDA approval covers breast cancer, often as first-line or extended adjuvant therapy in postmenopausal women, where the goal is aggressive, near-total estrogen suppression. Off-label, that same potency is a double-edged sword for TRT/AAS use: the margin between “estradiol in range” and “estradiol crashed” is much narrower than with anastrozole. Harm-reduction guidance in the community generally recommends against routine, ongoing letrozole use for estrogen management, reserving it instead for acute, short-duration situations — a gynecomastia flare, for instance — rather than as a regular AI.

Dosing & why the math is unforgiving

The FDA dose is 2.5 mg once daily. Off-label doses for TRT/AAS are typically small fractions of a milligram, and often used for a short, defined stretch rather than continuously — the same potency that makes letrozole effective in oncology is exactly what makes routine off-label use risky.

Because an effective off-label dose is a small fraction of the tablet, plain tablet-splitting isn’t precise enough at this potency for most people.

Because effective off-label doses are such a small fraction of the tablet, many who use letrozole this way rely on a liquid dilution or a milligram scale rather than a pill cutter alone.

Half-life & what it means for frequency

Letrozole’s half-life is around 2 days, but per the FDA label, steady-state blood concentrations aren’t reached until 2 to 6 weeks of consistent daily dosing — meaning the full effect of any dose change doesn’t show up right away, and judging it too early is a common mistake.

That slow ramp is another reason letrozole is a poor fit for reactive, day-to-day AI dosing off-label: by the time labs reflect the effect of one dose, weeks may have passed. Stacking a dose change on top of another before the first one has fully played out compounds crash risk rather than correcting it.

What to track & the crash risk

The relevant labs are the same as any aromatase inhibitor — estradiol and a lipid panel — but with letrozole, tracking symptoms closely alongside the number matters even more, since community reports describe crashed-estrogen symptoms as more frequent and more severe with letrozole than with anastrozole at “typical” off-label amounts.

Joint pain or dryness, low libido, flat mood, and disrupted lipids are the same crash symptoms as any AI — they’re just more likely to show up quickly at letrozole’s potency. The standard response is to stop or space out dosing and let estradiol recover, rather than treating each symptom as something separate from the AI itself.

There’s also a longer-horizon risk worth flagging explicitly: aromatase inhibitors carry a labeled risk of accelerated bone-mineral-density loss, osteoporosis, and fracture with extended use — a separate issue from an acute estrogen crash, and one more reason letrozole is generally reserved for short, targeted use rather than an ongoing off-label AI. A baseline bone-density scan, with periodic follow-up for anyone on it long-term, is worth discussing with a prescriber.

Frequently asked questions